Telix Seneffe Production Facility: Progress Update
Melbourne (Australia) and Seneffe (Belgium) – 30 July 2021. Telix authorised to decommission first of two cyclotrons at Seneffe radiopharmaceutical production facility.
Telix has today announced that it has received authorisation from the Belgian Agence Fédérale de Contrôle Nucléaire (AFCN) to decommission the first of two cyclotrons housed at the Company’s licensed radiopharmaceutical production facility in Seneffe, Belgium. The authorisation means that the AFCN has accepted Telix’s decommissioning dossier, submitted with the support of SCK-CEN (the Belgian Nuclear Research Centre), and is satisfied that safety and operational requirements will be met.
Telix Seneffe General Manager, Sébastien Linard stated, “This authorisation represents a significant milestone for Telix as it enables the build-out of a state-of-the art radiopharmaceutical production facility that will ultimately serve as Telix’s primary EU manufacturing site. This outcome is also positive for the Wallonia region as Telix’s production footprint will create local employment and partnership opportunities, further contributing to Belgium’s impressive radiopharmaceutical ecosystem. We would like to thank our collaborator SCK-CEN and our radioprotection advisor Be.Sure ASBL for their support in developing the dossier for AFCN submission.”
To read the full ASX disclosure please click here.
To submit an expression of interest for future job opportunities at Seneffe please visit our careers page here.
To return to Telix’s homepage please click here.